Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study

Bone Marrow Transplantation
B KasperG Egerer

Abstract

Prognosis of patients with metastatic soft tissue sarcoma remains poor. Whether high-dose chemotherapy with stem cell support improves the long-term outcome for these patients is debatable. We present a prospective, single-institutional phase II study that enrolled 34 soft tissue sarcoma patients with advanced and/or metastatic disease. After four courses of chemotherapy consisting of doxorubicin and ifosfamide, responding patients in at least partial response (PR) were treated with high-dose chemotherapy (n=9); all other patients continued chemotherapy for two more cycles. After standard chemotherapy, PR (n=10), stable disease (SD, n=6) and progressive disease (PD, n=14) were attained for the evaluable patients. Twenty-nine patients died and five are alive with the disease. Median PFS was 11.6 months (range 8-15) for patients treated with high-dose chemotherapy (n=9) vs 5.6 months (range 0-19) for patients treated with standard chemotherapy. Median OS was 23.7 months (range 12-34) vs 10.8 months (range 0-39), respectively. The subgroup of patients treated with high-dose chemotherapy gained significant survival benefit. Nevertheless, high-dose chemotherapy as a possible consolidation strategy remains highly investigational.

References

Oct 1, 1995·Critical Reviews in Oncology/hematology·J VerweijT Tursz
Feb 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S JelićI Filipović-Ljesković
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S R PatelR S Benjamin
Aug 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P ReichardtD Crowther
Dec 9, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G SaeterE Hannisdal
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P ReichardtB Dörken
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Y BlayP Biron
Feb 22, 2002·Critical Reviews in Oncology/hematology·Giovanni RostiMaurizio Marangolo
Feb 22, 2002·Critical Reviews in Oncology/hematology·Peter Reichardt
Mar 4, 2008·Cancer Treatment Reviews·Shailendra VermaUNKNOWN Members of the Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care
May 13, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carolyn D SeibBrent T Shoji

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.